Skip to main content
Home

Search form

Open Close
  • Contact
  • News
  • FAQs
  • About
    • About
    • Concept
    • What's in it for you?
    • Objectives
    • Assets
      • ELF compound library
      • Public Compound Collection
      • EU Screening Centre
      • Honest Data Broker
    • Partners
      • EFPIA
      • SMEs
      • Academia
  • Results
    • Portfolio
    • Progress
    • Publications
    • News
    • Events
    • Testimonials
  • How to submit
    • Drug target & assays
    • How it works
    • Requirements
    • Rights and obligations
    • Supporting documents for proposal submission
  • ELF 2013-2018
    • Joint European Compound Library
    • Results 2013-2018
    • Videos
    • Rights and obligations (2013-2018)
 
HomeSitemap

Sitemap

  • About
    • About
    • Concept
    • What's in it for you?
    • Objectives
    • Assets
      • ELF compound library
      • Public Compound Collection
      • EU Screening Centre
      • Honest Data Broker
    • Partners
      • EFPIA
      • SMEs
      • Academia
  • Results
    • Portfolio
    • Progress
    • Publications
    • News
    • Events
    • Testimonials
  • How to submit
    • Drug target & assays
    • How it works
    • Requirements
    • Rights and obligations
    • Supporting documents for proposal submission
  • ELF 2013-2018
    • Joint European Compound Library
    • Results 2013-2018
    • Videos
    • Rights and obligations (2013-2018)

Secondary menu

  • Contact
  • News
  • FAQs
    • FAQ's
    • FAQ - Project General Aspects
    • FAQ - Screening proposals

Interested?

Find out how you can boost your drug discovery programme and submit your screening proposal today

 

Learn more

Follow us at

  • Twitter
  • Linkedin
  • Youtube
  • Subscribe to Newsletter
  • Terms and conditions
  • Sitemap
  • Privacy Policy
  • Cookie Policy
  • Disclaimer

© European Lead Factory and its partners. 

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n' 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution.

This project has also received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806948: ‘ESCulab: European Screening Centre; Unique Library for Attractive Biology’. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Medicines for Malaria Venture (MMV).